Nuwiq, Human cell line recombinant human factor VIII (Human-cl rhFVIII), 250IU, powder and solvent for solution for injection. Vial of powder and prefilled WFI syringe

Šalis: Australija

kalba: anglų

Šaltinis: Department of Health (Therapeutic Goods Administration)

Veiklioji medžiaga:

simoctocog alfa, Quantity: 250 IU

Prieinama:

Octapharma Australia Pty Ltd

INN (Tarptautinis Pavadinimas):

simoctocog alfa

Vaisto forma:

Injection, powder for

Sudėtis:

Excipient Ingredients: sucrose; sodium chloride; sodium citrate dihydrate; poloxamer; calcium chloride dihydrate; arginine hydrochloride

Vartojimo būdas:

Intravenous

Vienetai pakuotėje:

1 vial

Recepto tipas:

exempt from scheduling - Appendix A; prescription medicine

Terapinės indikacijos:

Treatment and prophylaxis of bleeding (also during and after surgery) in previously treated paediatric (>= 2 years) and adult patients with haemophilia A (congenital factor VIII deficiency). Nuwiq does not contain von Willebrand Factor and is thus not indicated to treat von Willebrand?s Disease.

Produkto santrauka:

Visual Identification: Nuwiq - white to off-white lyophilised powder,WFI - clear, colourless liquid; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 2 Years; Container Temperature: Store at 2 to 8 degrees Celsius

Autorizacija statusas:

Licence status A

Leidimo data:

2014-11-10